System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Prof Sébastien Salas is an expert in Oncology at Hôpitaux universitaires de Marseille (France). As of October 2026, ScienceLeadR ranks Sébastien Salas in the top 1% of experts worldwide for Squamous Cell Carcinoma of Head and Neck, Sarcoma and Carcinoma. Sébastien Salas has authored 263 publications, the most recent in 2026, and is an investigator in 50 clinical trials, 14 of them ongoing. SLR score: 1,649 (community average: 125). How the SLR is computed.

LeadR Profile

Prof Sébastien Salas Hôpitaux universitaires de Marseille France
1 649 ScienceLeadR Reputation 1649

Unlock

Register Login
Network Map

Oncology

Subspecialties: Palliative Medicine - Radiotherapy - Otolaryngology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2006 - 2026
Source: PubMed

Hôpitaux universitaires de Marseille

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 263

Citations

Citations: 5 948 1st author: 33 Last author: 46 Unique author: 0

Main journals

J Clin Oncol 39
Ann Oncol 34
Cancer Res 10
Eur J Cancer 10
Int J Radiat Oncol Biol Phys 8

Best Journals

Ann Oncol 23
J Clin Oncol 16
Lancet Oncol 3

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
The Impact of Upfront DihydroPyrimidine Dehydrogenase (DPD) Testing on the Therapeutic Management of Patients Scheduled for 5-FU.
PMID 42728745 — dihydrouracil dehydrogenase (nadp), research design, uracil, oxidoreductases, neoplasms, fluorouracil, therapeutics		Cancer Med20260
The current State of supportive care in cancer: a national survey of healthcare providers and patients by the AFSOS.
PMID 42601525 — neoplasms, health personnel, palliative care		Support Care Cancer20260
Droplet Digital PCR Assessment of MDM2 Amplification in Liposarcoma Diagnosis and Prognosis: A French Single-Center Cohort Study.
PMID 42589586 — liposarcoma, polymerase chain reaction, neoplasms, cohort studies, survival analysis, diagnosis, prognosis		Int J Mol Sci20260
Continuous Intravenous Lidocaine for Refractory Cancer Pain in Palliative Care: A Multicenter Feasibility Study.
PMID 42536632 — feasibility studies, terminal care, pain, neoplasms, palliative care, lidocaine, neuralgia, cancer pain		J Palliat Care20260
Correction to: The CetuxIMAX study: a population pharmacokinetic approach to modelling the pharmacokinetics and pharmacodynamics relationships of Cetuximab in patients with head and neck cancer.
PMID 42470471 — cetuximab, neoplasms, head and neck neoplasms, pharmacokinetics		Cancer Chemother Pharmacol20260

Clinical Studies 50

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 6 Sub-Investigator: 1

By phase:

Phase 3 17
Phase 2 13
N/A 11
Phase 1/Phase 2 5
Phase 1 4

By status:

Recruiting 13
Completed 12
Active not recruiting 10
Unknown 9
Terminated 5
Not yet recruiting 1

By type:

Interventional 44
Observational 6

By Monocentric/Multicentric:

monocentric 9
multicentric2to4 1
multicentric5to9 3
multicentricup10 37

Main Topics

Ongoing Clinical Trials

14 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A phase 3 study to evaluate petosemtamab vs investigator s choice in previously treated metastatic recurrent head and neck cancer
2023-510322-32-00 — cells, safety, carcinoma, squamous cell, neoplasms, squamous cell carcinoma of head and neck, head and neck neoplasms, therapeutics, carcinoma, head, neck		Phase 3Active not recruiting2025
A Study of JNJ 90301900 in Combination with Concurrent Chemoradiation Therapy in LA HNSCC
2025-522914-22-00 — squamous cell carcinoma of head and neck, therapeutics		Phase 1Recruiting2026
A phase 3 study to evaluate petosemtamab plus pembrolizumab vs pembrolizumab in first line treatment of head and neck cancer
2023-510323-30-00 — cells, safety, carcinoma, squamous cell, neoplasms, squamous cell carcinoma of head and neck, head and neck neoplasms, therapeutics, carcinoma, head, neck		Phase 3Recruiting2025
A Study of Amivantamab in Addition to Standard of Care Agents Compared with Standard of Care in Participants With Recurrent Metastatic Head and Neck Cancer
2025-521917-24-00 — cells, carcinoma, squamous cell, neoplasms, fluorouracil, squamous cell carcinoma of head and neck, head and neck neoplasms, therapeutics, carboplatin, carcinoma, head, neck		Phase 3Not yet recruiting2026
Study of Taxane Platinum followed by a maintenance with avelumab and cetuximab in First Line Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
2023-510559-41-00 — cells, cetuximab, carcinoma, squamous cell, drug therapy, maintenance, squamous cell carcinoma of head and neck, chemotherapy, carcinoma, head, neck		Phase 2Recruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS